Rolex Rings Limited Initial Public Offer to open on July 28, 2021

 

Rolex Rings Limited Initial Public Offer to open on July 28, 2021

 

·         Price Band fixed at ₹880 to ₹900 per equity share of face value of ₹10 each of Rolex Rings Limited (“Equity Share”)

·         Offer to remain open from Wednesday, July 28, 2021 to Friday, July 30, 2021

·         Minimum Bid Lot is 16 Equity Shares and in multiples of 16 Equity Shares thereafter.

·         The Floor Price is 88.0 times the face value of the Equity Shares and the Cap Price is 90 times the face value of the Equity Shares. 

 

Mumbai, July 26, 2021: Rolex Rings Limited (the “Company”), one of the top five forging companies in India in terms of installed capacity (Source: ICRA Report), proposes to open its initial public offering of its Equity Shares (“Offer”) on July 28, 2021.

 

The Price Band of the Offer has been fixed at ₹880 to ₹900 per Equity Share. Bids can be made for a minimum of 16 Equity Shares and in multiples of 16 Equity Shares thereafter.

 

The Offer comprising of a fresh issue aggregating up to ₹560 million (the “Fresh Issue”) and an offer for sale by Rivendell PE LLC, (the “Selling Shareholder”), of up to 7,500,000 Equity Shares.

 

The Offer is being made in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended (“SCRR”) read with Regulation 31 of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (“SEBI ICDR Regulations”). The Offer is being made through the Book Building Process in accordance with Regulation 6(1) of the SEBI ICDR Regulations, wherein not more than 50% of the Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers (“QIB Portion”), provided that the Company and the Selling Shareholder in consultation with the BRLMs may allocate up to 60% of the QIB Portion to Anchor Investors, on a discretionary basis (“Anchor Investor Portion”). One-third of the Anchor Investor Portion shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of undersubscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5% of the QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining QIB Portion for proportionate allocation to QIBs.

 

Further, not less than 15% of the Offer shall be available for allocation on a proportionate basis to Non-Institutional Bidders and not less than 35% of the Offer shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount (“ASBA”) process providing details of their respective ASBA accounts and UPI ID (in case of RIBs), in which the corresponding Bid Amounts will be blocked by the SCSBs or under the UPI Mechanism, as applicable. Anchor Investors are not permitted to participate in the Offer through the ASBA process.

 

The Company proposes to utilise the Net Proceeds from the Fresh Issue towards (i) Funding long-term working capital requirements; and (ii) General corporate purposes.

 

Equirus Capital Private Limited, IDBI Capital Markets & Securities Limited and JM Financial Limited are the Book Running Lead Managers to the Offer.

 

The Equity Shares to be offered through the Red Herring Prospectus are proposed to be listed on BSE and NSE.